Replies to post #773608 on NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

Brooktrail, Well said. DCVax is indeed a paradigm shift treatment.

Longs know truly DISRUPTIVE change requires nurturing and a bit of growing roots below the surface, and when it emerges, it will be like a giant Moso Bamboo:

Running Bamboos primarily spread through extensive underground root systems called rhizomes. This is crucial for the plant to store energy and nutrients, and it can take a few years for a young plant to establish a robust rhizome system. During this initial period, you might see limited above-ground growth.

However once the underground rhizome system is well-established and conditions are favorable (typically in spring), the bamboo sends up new shoots (culms) from the nodes on these rhizomes. These new culms emerge from the ground at their full diameter and then grow to their mature height incredibly quickly, some species growing over 3 feet in 24 hours.

NWBO has been very active below the surface:
- vaccine (not drug)
- personalized, non-toxic, holistic response, immune memory
- broad spectrum cancer vaccine (DCs and MOA are tumor agnostic, stage agnostic)
- acquiring Flaskworks (automation, low cost mfg)
- acquiring Roswell Cancer Center's families of IP/patents for dendritic cells, including two Ph2 clinical trials
- first systemic drug treatment to achieve significant results in a Phase 3 clinical trial in decades for nGBM and rGBM
- built and own a state-of-the-art live cell mfg facility (Sawston, UK)
- next-gen DCVax-Direct product (Phase 2 trials about to begin)
- continual cutting-edge tech: genomic sequencing (Dr Ashkan), proteomics (Dr. Bosch), poly-iclc / adjuvants (Dr. Liau), tumor microenvironment (Roswell)
- creating a DCVax ecosystem ("Franchise")
- establishing a dominating moat in the DC therapy space
- MHRA Draft Guidelines on ECA, effective July 2025 (speculate NWBO participation)
- SI 2025 No 87, legislation for Modular Manufacturing and POC, effective July 2025 (speculate NWBO participation)

Due diligence + Investor calm = investing discipline.

[manibiotech]

So then why didn't she submit BLA to FDA by your logic . Why has she been waiting ? You can't have it both ways